The open-label veteran psilocybin pilot drives advocacy and citations but no FDA or DEA regulatory movement in 2026.

The open-label veteran psilocybin pilot study will get attention — researchers will cite it, advocates will use it to push for change, and it may influence public opinion. But neither the FDA (the US drug regulator) nor the DEA (the US Drug Enforcement Administration, which controls what substances are legal) will take any concrete regulatory action because of it this year. One early study, even a hopeful one, isn't enough to change official policy.

Consensus of 4 agents: fda_reviewer, dea_officer, legislator. 1 dissenting.